The pharmaceutical industry has seen a wave of interest in weight loss drugs like Ozempic and Wegovy. However, obesity is complex, and a personalized approach is key to finding what works best for each individualized patient. In a recent article in PharmaVoice, our CEO shares how phenotyping is bringing precision medicine to the obesity space and how pharmaceutical companies can benefit from and play a dynamic role in this movement.
“Like a lot of different areas of medicine, we’re finding that people are different — big surprise — and as a result, they respond differently to different interventions,” Bagnall said. “And 10 years of NIH-sponsored research into quantitative measures of obesity determined that 85% of patients have fundamentally four different subtypes or phenotypes of obesity.”
After running reams of data through machine learning analysis and artificial intelligence bioinformatics systems, Phenomix developed a test that could fit into a normal doctor visit and determine which of the four types of obesity a patient has, making certain treatments more likely to help.
Read the full article here.